Araris Biotech AG, a Swiss oncology biotech company developing next-generation antibody drug conjugates (ADCs), has announced its first collaboration agreement. The Swiss start-up will use its proprietary linker-conjugation platform to generate novel ADCs against undisclosed targets provided by Taiho Pharmaceutical Co., Ltd..

开发下一代抗体-药物偶联物（ADC）的瑞士肿瘤生物技术公司Araris Biotech AG宣布了其首次合作协议。瑞士初创公司将使用其专有的连接子结合平台，针对大和制药有限公司提供的未公开目标生成新型ADC。。

Araris Biotech is a pioneering leader in the development of antibody-drug conjugates (ADCs) with the potential for high efficacy and tolerability. With a strong commitment to transforming the landscape of ADCs, Araris leverages its proprietary, ready-to-use linker-payload platforms and site-specific conjugation techniques to create a new frontier in targeted therapeutics..

Araris Biotech是抗体-药物偶联物（ADC）开发的开拓性领导者，具有高效率和耐受性的潜力。Araris致力于改变ADC的格局，利用其专有的即用型接头有效负载平台和特定于位点的偶联技术，在靶向治疗领域创造了新的前沿。。

The company entered a collaboration with Taiho Pharmaceutical, a Japanese R&D-driven specialty pharma company with a focus on oncology. ADCs delivered by Araris will be further tested and evaluated by Taiho. The financial terms of the collaboration agreement were not disclosed.

该公司与日本研发驱动的专业制药公司Taiho Pharmaceutical合作，专注于肿瘤学。Araris提供的ADC将由Taiho进一步测试和评估。没有披露合作协议的财务条款。

“We are proud to enter a collaboration with Taiho Pharmaceutical and look forward to working with the Taiho team to develop next-generation ADCs with improved efficacy and tolerability,” said Dragan Grabulovski, Ph.D., acting chief executive officer of Araris.

Araris代理首席执行官Dragan Grabulovski博士说：“我们很自豪与Taiho Pharmaceutical合作，并期待与Taiho团队合作开发具有更高功效和耐受性的下一代ADC。”。

Philipp Spycher, Ph.D., chief scientific officer of Araris added, “This agreement underlines the potential of our linker-payload platform to deliver novel ADCs with excellent properties, and it positions our company as a highly attractive partner for pharmaceutical companies.”

Araris首席科学官Philipp Spycher博士补充说：“该协议强调了我们的连接器有效载荷平台提供具有优异性能的新型ADC的潜力，并使我们的公司成为制药公司极具吸引力的合作伙伴。”

(Press release / SK)

（新闻稿/SK）

0Comments

0常见

Back to all news

回到所有新闻

Please login

请登录

or sign up

或者注册

to comment.

评论。

Commenting guidelines

评论指南

Send

发送